

This list is composed of 65 genes associated with inherited cancer syndromes included on the xT panel and selected based on recommendations from the American College of Medical Genetics (ACMG), the National Comprehensive Cancer Network (NCCN) and/or published literature^{1,2}.

The primary focus of the xT panel is somatic reporting. Tempus also offers separately ordered validated germline hereditary cancer panels through GeneDx.

GERMLINE INCIDENTAL FINDINGS GENE LIST

APC: APC-associated conditions

ATM: Ataxia-Telangiectasia, Breast cancer susceptibility, Pancreatic cancer susceptibility

AXIN2: Oligodontia-colorectal cancer syndrome

BAP1: BAP1 tumor predisposition syndrome

BARD1: Breast cancer susceptibility

BLM: Bloom syndrome

BMPRIA: Juvenile polyposis

BRCA1: Hereditary breast and ovarian cancer

BRCA2: Hereditary breast and ovarian cancer, Fanconi anemia

BRIP1: Ovarian cancer susceptibility, Fanconi anemia

CDH1: Hereditary diffuse gastric cancer, Breast cancer susceptibility

CDK4: Melanoma susceptibility

CDKN2A: Melanoma-pancreatic cancer syndrome

CEBPA: Acute myeloid leukemia susceptibility

CHEK2: Breast cancer susceptibility, Colon cancer susceptibility

DICER1: DICER1 tumor predisposition syndrome

EGFR: Lung cancer susceptibility, TKI resistance

EPCAM*: Lynch syndrome

ETV6: Leukemia susceptibility, thrombocytopenia susceptibility

FH: Hereditary leiomyomatosis and renal cell cancer

FLCN: Birt-Hogg-Dube syndrome

GATA2: GATA2 deficiency with susceptibility to myeloid malignancies

KIT: Familial gastrointestinal stromal tumor

MAX: Hereditary paraganglioma-pheochromocytoma syndrome

MEN1: Multiple endocrine neoplasia type 1

MET: Hereditary papillary renal cell carcinoma

MLH1: Lynch syndrome, Constitutional mismatch repair deficiency

MSH2: Lynch syndrome, Constitutional mismatch repair deficiency

MSH3: MSH3-associated polyposis

MSH6: Lynch syndrome, Constitutional mismatch repair deficiency

MUTYH: MUTYH-associated polyposis

NBN: Nijmegen breakage syndrome, Breast cancer susceptibility

NF1: Neurofibromatosis type 1

NF2: Neurofibromatosis type 2

NTHL1: NTHL1 tumor syndrome, NTHL1-associated polyposis

PALB2: Breast cancer susceptibility, Pancreatic cancer susceptibility, Ovarian cancer susceptibility, Fanconi anemia

PDGFRA: Familial gastrointestinal stromal tumor, GIST-plus syndrome

PHOX2B: Neuroblastoma susceptibility

PMS2: Lynch syndrome, Constitutional mismatch repair deficiency

POLD1: Polymerase proofreading-associated polyposis

POLE: Polymerase proofreading-associated polyposis

PRKAR1A: Carney complex

PTCH1: Gorlin syndrome, Basal cell nevus syndrome

PTEN: PTEN hamartoma tumor syndrome

RAD51C: Ovarian cancer susceptibility, Breast cancer susceptibility, Fanconi anemia

RAD51D: Ovarian cancer susceptibility, Breast cancer susceptibility

RBI: Retinoblastoma

RET: Multiple endocrine neoplasia type 2, Familial medullary thyroid cancer

RUNX1: Acute myeloid leukemia susceptibility

SDHA: Hereditary paraganglioma-pheochromocytoma syndrome

SDHAf2: Hereditary paraganglioma-pheochromocytoma syndrome

SDHB: Hereditary paraganglioma-pheochromocytoma syndrome

SDHC: Hereditary paraganglioma-pheochromocytoma syndrome

SDHD: Hereditary paraganglioma-pheochromocytoma syndrome

SMAD4: Juvenile polyposis, Hereditary hemorrhagic telangiectasia

SMARCA4: Rhabdoid tumor predisposition syndrome

SMARCB1: Rhabdoid tumor predisposition syndrome, Schwannomatosis

STK11: Peutz-Jeghers syndrome

SUFU: Gorlin syndrome, Basal cell nevus syndrome

TMEM127: Hereditary paraganglioma-pheochromocytoma syndrome

TP53: Li-Fraumeni syndrome

TSC1: Tuberous sclerosis complex

TSC2: Tuberous sclerosis complex

VHL: Von Hippel-Lindau syndrome

WT1: WT1-related Wilms tumor

1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic V.2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed [July 19, 2022]. To view the most recent and complete version of the guideline, go online to NCCN.org.

2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal V.1.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed [July 19, 2022]. To view the most recent and complete version of the guideline, go online to NCCN.org.

* Includes promoter region

** Genes in which incidental germline findings are reported

In addition to reporting on somatic variants, when a normal sample is provided, Tempus reports germline incidental findings on a limited set of variants associated with inherited cancer syndromes within 65 genes selected based on recommendations from the American College of Medical Genetics (ACMG), the National Comprehensive Cancer Network (NCCN), and/or published literature.

t Exons and select intronic regions only. Additional coverage information provided upon request.

‡ Special reporting – EGFR: p.T790M, p.L792H, p.C797G, p.C797S (resistance alterations only); EPCAM: Large deletions only; POLD1: Exonuclease domain only; POLE: Exonuclease domain only.